本日も有難う御座いました

本日8日ゲスト出勤

18:00-2:00
ゐなな
@inana_aa

次回ゲスト
13日
18:00-23:00
工藤らるな
@Lily_laluna_

14日
21:00-5:00
三毛
@calicocat_meow3

15日
17:00-23:00
れいあ
@Rei_a_1323

#ゲスト出勤 #アイドル #コンカフェ #コスプレ

Japanese researchers have successfully engineered miniature human livers—grown entirely from stem cells—that perform key liver functions such as protein synthesis and toxin filtration. These bioengineered organs were transplanted into mice with liver failure, and astonishingly, they restored liver function and saved the animals’ lives. This is a major leap in regenerative medicine, demonstrating not just the ability to replicate complex organ tissue, but also its functionality in living systems.

The long-term vision is to scale this technology for use in human patients, especially those on long organ transplant waiting lists. With millions of people suffering from chronic liver conditions worldwide, lab-grown livers could become a lifesaving alternative to donor organs. As the science progresses, this innovation may also help reduce rejection risks by allowing livers to be grown from a patient’s own cells, offering hope for a future where organ failure doesn’t mean a death sentence.

#RegenerativeMedicine #StemCellResearch #LiverTransplant #MedicalBreakthrough #Bioengineering

In a medical breakthrough that could reshape the future of HIV treatment, researchers have successfully used CRISPR/Cas9 gene-editing technology to eliminate HIV from human T-cells—and in follow-up lab tests, the virus did not return. This marks a major shift from traditional antiretroviral therapies, which only suppress viral replication but cannot remove the virus embedded in the host's DNA. By directly excising the proviral HIV-1 genome from immune cells, this technique targets the root of the infection—something decades of treatments have struggled to achieve.

What makes this discovery even more promising is that the edited immune cells were not only HIV-free but also resistant to reinfection. That suggests a future where patients might receive a one-time treatment capable of permanently curing HIV. While human clinical trials are still in early stages and much research remains, the results signal hope for millions living with the virus. If proven safe and effective in broader applications, this could become one of the most transformative moments in medical history.

#HIVCure #GeneEditing #CRISPR #MedicalBreakthrough #FutureOfMedicine

Scientists at the University of Sunderland, led by Dr. Maria Teresa Borrello, have developed two experimental drugs—DR-3 and FDR2—that target the enzyme HDAC6.

These drugs have shown promise in halting or reversing liver fibrosis, a condition characterized by the accumulation of scar tissue in the liver.

Research Overview

The research, published in The FEBS Journal, focuses on the role of HDAC6 in liver fibrosis.

HDAC6 is involved in regulating inflammation and the activation of hepatic stellate cells, which are responsible for producing collagen and contributing to scar tissue formation.

By inhibiting HDAC6, the experimental drugs aim to reduce inflammation and prevent the activation of these stellate cells, thereby mitigating fibrosis progression.

Laboratory Findings

In laboratory settings, the HDAC6 inhibitors DR-3 and FDR2 demonstrated high selectivity for HDAC6 over other histone deacetylases.

They effectively reduced markers of hepatic stellate cell activation and fibrogenic gene expression.

Additionally, these compounds increased acetylation of α-tubulin and suppressed TGF-β1-induced SMAD signaling, which are key pathways in fibrosis development.

Ex Vivo Human Liver Models

The efficacy of DR-3 and FDR2 was further validated using human precision-cut liver slices (hPCLS), an ex vivo model that closely mimics human liver tissue.

Treatment with these inhibitors resulted in reduced fibrogenic protein levels and collagen deposition, indicating their potential to reverse existing fibrosis.

Importantly, these effects were achieved without significant toxicity to the liver tissue.

Clinical Implications

The British Liver Trust has welcomed these findings, highlighting their potential to transform care for the UK's estimated two million liver fibrosis patients, many of whom are diagnosed at advanced stages of the disease.

While these results are promising, the drugs are still in the experimental phase and have not yet undergone human clinical trials. Nevertheless, they offer a targeted therapeutic approach that could eventually become a lifesaving treatment worldwide.

Spanish Zarzuela de Mariscos – Catalan Seafood Medley

A luxurious seafood stew from Catalonia, Zarzuela is made with a medley of shellfish and fish in a saffron-tomato-white wine sauce, often served at special occasions.

Ingredients (Serves 4):

* 200g shrimp
* 200g mussels
* 200g clams
* 300g firm white fish (hake, monkfish)
* 1 onion, chopped
* 2 garlic cloves, minced
* 2 tomatoes, peeled and chopped
* 100ml white wine
* 1 pinch saffron threads
* Olive oil, salt, pepper, parsley

Instructions:

1. Sauté onion and garlic in olive oil. Add tomatoes and saffron, cook until thickened.
2. Pour in white wine and simmer.
3. Add fish, then mussels, clams, and shrimp. Cover and steam until shellfish open and fish is cooked.
4. Season and garnish with parsley. Serve with toasted bread.

Catalan Tip:
For extra richness, blend a paste of almonds and garlic (picada) and stir in before serving.